EBR is a U. S. based medical device company that developed the WiSE CRT System, an implantable cardiac pacing system that delivers stimulation to endocardial heart tissue to correct heart rhythm conditions without the use of leads. The WiSE CRT System functions as part of cardiac resynchronization therapy (CRT) by providing left ventricular pacing that works alongside an existing right ventricular pacing device. The system consists of an implantable electrode placed in the left ventricular endocardium, a subcutaneous transmitter that contains a battery and an ultrasound transducer, a delivery catheter used to implant the electrode, and a programmer that adjusts device settings. The transmitter detects the right ventricular pacing pulse from the co implanted device and, within a few milliseconds, emits an ultrasonic pulse that the electrode converts into electrical energy to stimulate the heart. By eliminating the need for traditional leads, the system aims to reduce complications associated with lead based implants such as lead fracture, infection and venous obstruction, and expands CRT access to patients who cannot receive or are at high risk from conventional lead implantation.
The company generates revenue primarily from the sale of the WiSE CRT System to hospitals and cardiac care facilities. Each system includes the implantable electrode, the subcutaneous transmitter with battery, the delivery catheter and the programmer. Revenue is recognized upon implantation of the system in patients who meet the FDA approved indications. In addition to product sales, the company may receive fees for device programming, technical support and training services provided to implanting physicians and hospital staff. Because the WiSE CRT System received FDA approval in April 2025 and is still in the early commercialization phase, current revenue reflects limited initial sales as the company builds its sales force and expands its market presence. The long term growth strategy depends on increasing the number of implants per site, broadening the geographic reach of its sales organization and securing favorable reimbursement coverage from private insurers and government programs.
EBR occupies a distinctive niche in the cardiac rhythm management market as the sole provider of a leadless left ventricular pacing solution that can be paired with an existing right ventricular device to deliver biventricular pacing. Major competitors such as Medtronic, Boston Scientific, and Abbott offer leadless pacemakers that are limited to right ventricular or atrial placement and do not provide left ventricular therapy. EBR’s technology, which converts ultrasound energy into electrical energy to pace the heart, offers a novel approach that avoids the mechanical failure risks associated with leads. The company’s robust patent portfolio, comprising 59 granted U. S. patents and 38 granted non US patents, further strengthens its competitive position by protecting key aspects of the WiSE CRT System including the transducer, electrode, and programmer. Clinical data from the SOLVE CRT trial demonstrated a 16.4% reduction in left ventricular end systolic volume and an 80.9% freedom from device or procedure related complications at six months, supporting the safety and efficacy of the system. Furthermore, the FDA granted breakthrough device designation to the WiSE CRT System, which makes it eligible for incremental payment programs such as the New Technology Add On Payment and Transitional Pass Through reimbursement, providing a potential advantage over existing therapies.
The company serves hospitals and cardiac electrophysiology centers that perform implantable device procedures. Specific customer names are not disclosed in the filing, but the target market includes high volume hospitals in the United States and selected international sites in regions such as Australia, the United Kingdom, and the European Union. These institutions are selected based on their procedural volume and expertise in cardiac resynchronization therapy. In addition, EBR focuses on academic medical centers and large community hospitals that have dedicated heart failure programs and electrophysiology labs capable of performing complex leadless implants. The company also works with distributors and specialty suppliers to ensure reliable delivery of the WiSE CRT System to its end users.